1 Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -
2 Bladder Cancer Madhusudan P Koya FRCS; FRACS Consultant Urologist Onesixone Medical Group, Auckland
3 Bladder cancer: Epidemiology Incidence: new cases per year [2016-USA] Mortality: deaths per year [2016-USA] Fourth most common cancer in men Seventh most common cancer in women At diagnosis >70%: > 65 y of age
4 Bladder Cancer in NZ 370 [270M] new registrations per year 170 [118M] deaths per year Maori:Non Maori 1:1 [from 1:2.5 in 1997] Steady death rate with no decline in the last 15 years Incidence has also remained steady
5 Bladder Cancer Bladder cancer is the fifth most common cancer in the Western world and is on the rise. Most patients present with superficial disease and are treated by transurethral resection of bladder tumour. More than half of these patients experience recurrence with about 20% progressing to muscle invasive disease. Muscle invasive cancer is treated by Radical Cystectomy or Chemoradiation
7 Clinical Features Visible Haematuria Dysuria Abdominal pain Constipation UTI Raised Creatinine Raised inflammatory markers Raised WCC
10 Visible haematuria With a high PPV of 2.6% this remains the main clinical feature in primary care that must lead to investigations and follow up
11 The Problem Is it cancer? Is it an emergency? Can I ignore it?
12 Emergencies Heavy Bleeding Causing Hypovolaemia Clot Urinary Retention Anaemia
13 Other Causes of Red Urine Myoglobin, Haemoglobin Porphyrins Phenolpthalien (laxatives) Rifampicin, Phenothiazines Betroot, Rhubarb.
14 Frank V Microscopic Malignancy could present as frank or microscopic haematuria
15 Classical description 1 Gross Total Painless Haematuria TCC Bladder
16 Normal? More than 3 RBC per High power field is abnormal
17 Classical description 2 Gross Haematuria with Flank Pain/Mass Renal Cell Cancer
18 Classical description 3 Loin - GroinPain Microscopic Blood Stone
19 Gross Haematuria Most Common site in order: 1. Bladder 2. Prostate 3. Kidney/Ureter 4. Other
20 Gross Haematuria Common Causes 1st 2nd 3rd Inflammation Neoplasia Foreign Body
21 Microscopic Haematuria 80% -No Important Cause Found 20% -Important Cause found
22 Haematuria 15-20% of cases with macroscopic haematuria had malignancy 10% of patients with microhaematuria had malignancy
23 Investigations? Microscopic Haematuria Microscopy to confirm Ultrasound Urine cytology Cystoscopy Further investigations [CTIVU] to be considered. Follow up?
24 Investigations? Always Investigate Gross Haematuria Ultrasound Urine Cytology Cystoscopy Consider CTIVU, RGP, Ureteroscopy Etc. If cause not found
25 Testing for Bladder cancer White light cystoscopy is the gold standard with a sensitivity of 90% But invasive and expensive Limits compliance Urine cytology is highly specific [99%] but limited by Low sensitivity [34%] especially in low grade Inter observer variations
26 Need for a good biomarker To improve management Improve quality of life of patients Decrease morbidity associated with current tests *A noninvasive, highly sensitive and specific marker required
27 Need for a good biomarker A good diagnostic marker should Have a low false positive rate A good surveillance marker should Have a high sensitivity and High negative predictive value
31 Bladder cancer: Histology 75-85% Nonmuscle invasive bladder cancer pta [70%], ptis [10%], pt1 [20%] 10-15% muscle-invasive bladder cancer pt2, pt3, pt4 5% metastatic bladder cancer N+, M+
32 Bladder cancer: Stage and Prognosis Stage TNM 5-y. Survival 0 Ta/Tis N0M0 >85% I T1 N0M % II T2a-b N0M0 57% III T3a-4a N0M0 31% IV T4b N0M0 24% Any T N+Mo 14% Any T M+ med. 6-9 Mo
33 Nonmuscle invasive Bladder Cancer pta, pt1, Tis Standard of care transurethral resection Relapse rate: 70% Progression rate 30% *Due to the recurrence rate highest lifetime treatment cost per person of all cancers
34 Nonmuscle invasive Bladder Cancer Histological grading is important G1 G2 G3 Relapse rate 42% 50% 80% Progression rate 2% 11% 45%
35 Invasive bladder cancer 5 year survival is 38% Standard of care = Radical cystectomy with pelvic lymphadenectomy Only about 50% of patients with high-grade invasive disease are cured
36 Results of radical cystectomy Stage Recurrence-Free Overall Survival 5 y. 10y. 5 y. 10y. T2 N N T3a N N T3b N N T4a N N Stein et al JCO 2001;19:666
37 Results of radical cystectomy Stage Recurrence-Free /Overall Survival 5 years Organ-confined (<pt2pno) 73% 62% non-organ-confined (>pt2pno) 56% 49% Positive lymph nodes (pt1-4, pn+) 33% 24% Madersbacher et al JCO 2003;21:690
38 Adjuvant chemotherapy Six randomised trials have compared CT with observation after cystectomy or RT 4x no survival benefit 2x benefit from adjuvant CT no standard of care node positive disease, lymphovascular invasion, positive margins
39 Neoadjuvant chemotherapy Meta-analysis of ten randomised trials (2688 patients) 13% reduction in risk of death 5% absolute benefit at 5 years OS increased from 45% to 50% ABC Meta-analysis Collaboration. Lancet 2003;361:1927
40 Combined Radio- and Chemotherapy CR 5y.OS Radiotherapy 57% 47% RT and cisplatin 85% 69% RT and carboplatin 70% 57% Birkenhake et al. Strahlenther Onkol 1998;174:121
41 Bladder-sparing therapy for invasive bladder cancer High probability of subsequent distant metastasis after cystectomy or radiotherapy alone (50% within 2 years) Radiotherapy im comparison with cystectomy has inferior results (local control 40%) muscle-invasive bladder cancer is often a systemic disease combined modality therapy
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
Guidelines for the Management of Bladder Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Version 3 and 4 Sections 5.2 and 8 updated Page 1 of 9 1. Scope of
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer Reference: NHS England B14X08 Information Reader Box (IRB) to be inserted on inside front cover for documents of 6
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
european urology 55 (2009) 911 921 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Bladder Preservation in Selected Patients with Muscle-Invasive Bladder Cancer
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
Tissue Source Site (TSS) Name: TSS Identifier: _ TSS Unique Patient #: Completed By: Completion Date (MM/DD/YYYY): Form Notes: An Enrollment Form should be completed for each TCGA qualified case upon qualification
Vagina 1. Introduction 1.1 General Information and Aetiology The vagina is part of internal female reproductive system. It is an elastic, muscular tube that connects the outside of the body to the cervix.
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
UICC TNM 8 th Edition Errata ions are in italics Head and Neck Tumours Pages 20, p27, p34, p38, p41, and p49 ly pn2a Metastasis in a single ipsilateral lymph node, less than 3cm in greatest dimension with
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2015) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg
Bladder cancer: diagnosis and management NICE guideline Published: 25 February 2015 nice.org.uk/guidance/ng2 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
: F Diseases Volume 16 Issue 1 Version 1.0 Year 2016 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN: 0975-5888
Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Sam S. Chang, MD, MBA Patricia & Rodes Hart Chair Professor of Urologic Surgery & Oncology Vanderbilt University Medical
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging
CLINICAL PRESENTATION This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson,
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
european urology 51 (2007) 1281 1288 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Transitional Cell Carcinoma of the Ureter: Prognostic Factors Influencing
Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens Harman Maxim Bruins,* Hooman Djaladat,* Hamed Ahmadi, Andy
Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy Authors: Dr Gordon Armstrong, Dr Sue Pritchard 1. General Comments 1.1 Cancer reporting: Biopsies
Network Guidance Document Oncological Treatment of Urological Cancer Status: Expiry Date: Version Number: Publication Date: Final March 2014 8 March 2012 Page 1 of 13 Contents Contents... 2 Oncology Provision...
BLADDER HEALTH Non-Muscle Invasive Bladder Cancer: A Patient Guide Table of Contents Non-Muscle Invasive Bladder Cancer Expert Panel Patient Story.... Introduction.... GET THE FACTS What is bladder cancer?....
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
CANCER CERVIX Most common cancer Africans & Asians more prone because of poor socioeconomic condition Drastic decline in west as more detection of preinvasive leison by PAP Smears. Etiology: Age - 2 peaks
Rectum Adenocarcinoma Quality of conformal radiotherapy Impact for the surgeon P. Scalliet & K. Haustermans Fifth Belgian Surgical Week May 6th, 2004, Oostende SOR rectum adenocarcinoma Indication of radiotherapy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 6 Fluorescence in situ Hybridization (FISH) Principles
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
Shen et al. World Journal of Surgical Oncology (2017) 15:192 DOI 10.1186/s12957-017-1259-4 RESEARCH Analysis of the causes of failure after radical surgery in patients with P T 3 N 0 M 0 thoracic esophageal
The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,
European ssociation of Urology Pocket Guidelines 2016 edition European ssociation of Urology Pocket Guidelines 2016 edition Introduction We are honoured to present the 2016 edition of the EU Pocket Guidelines.
Bettina Kandel Like surgery radiotherapy is usually a localized type of treatment. Today it is more readily available for the treatment of cancer in companion animals and many clients are well informed
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
BLADDER HEALTH Muscle Invasive Bladder Cancer: A Patient Guide Table of Contents Bladder Cancer Expert Panel Mike's Story: A Patient Story.... Introduction.... GET THE FACTS What is bladder cancer?....
Guidelines for the management of renal cancer Approved by the urology pathway board September 2014 To be reviewed September 2016 Renal Cancer Guidelines 1. Introduction 1.1 Kidney cancer accounts for 3%
Bladder EpiCheck Is A Sensitive and Specific Novel Molecular Diagnostic Tool for Monitoring Of Bladder Cancer Patients Wasserstrom A 1., Frumkin D., Dotan Z. 3, Bukin E. 1, Gadish T 1., Hanuka S. 1, Knirsh
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors